Abstract Number: 1476 • ACR Convergence 2022
Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus
Background/Purpose: Enhanced netosis has been acknowledged as pathogenic in Systemic Lupus Erythematosus (SLE). The presence of antibodies against neutrophil extracellular traps (anti-NETs) in patients with…Abstract Number: 1631 • ACR Convergence 2022
Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with…Abstract Number: 1711 • ACR Convergence 2022
The Cellular Basis for Type I Interferon Production Following Ultraviolet Light Stimulated Cyclic-GMP-AMP Synthase Activation in the Skin
Background/Purpose: SLE patients characteristically have a type I interferon (IFN-I) signature in peripheral blood cells and this same signature is prominent in lesional and non-lesional…Abstract Number: 1932 • ACR Convergence 2022
Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
Background/Purpose: The COVID-19 virus has caused significant morbidity and mortality, despite introduction of the COVID vaccine. Immunocompromised patients have been shown to have reduced response…Abstract Number: 2063 • ACR Convergence 2022
Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
Background/Purpose: Medication cost concerns are associated with nonadherence and poor outcomes in the general population. Prior research has described medication cost concerns in up to…Abstract Number: 2081 • ACR Convergence 2022
COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk for severe disease from COVID-19 and decreased vaccine efficacy, due to inherent immune perturbations…Abstract Number: 2101 • ACR Convergence 2022
Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
Background/Purpose: Autoimmune Hemolytic Anemia (AIHA) is one of the manifestations of Systemic lupus erythematosus (SLE), an autoimmune connective tissue disease. AIHA may be present in…Abstract Number: 2225 • ACR Convergence 2022
Physical Inactivity Is Associated with Increased Expression of T Cell Inflammatory Genes in Systemic Lupus
Background/Purpose: Prior studies show an independent association between greater physical activity and lower inflammatory markers among adults in the general population, but the impact of…Abstract Number: 0063 • ACR Convergence 2022
Implementability of a SLE Medication Adherence Intervention
Background/Purpose: Medication nonadherence in SLE is common and negatively impacts patient outcomes. Yet, little is known about how to improve medication adherence in patients with…Abstract Number: 0116 • ACR Convergence 2022
Racial Differences in Medication Beliefs and Barriers to Taking Medications Among Patients with SLE
Background/Purpose: Medication adherence is critical for SLE management and can be influenced by patients' barriers and beliefs about treatment. Patients of color with SLE have…Abstract Number: 0329 • ACR Convergence 2022
Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression
Background/Purpose: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to important worsening of quality of life and mortality. Flares appear unpredictably during the…Abstract Number: 0347 • ACR Convergence 2022
Real-World Effectiveness of Belimumab in Patients with SLE in the United States
Background/Purpose: The aim of this study was to evaluate the real-world effectiveness of the disease-modifying treatment belimumab (BEL), comparing the rates of SLE flares among…Abstract Number: 0369 • ACR Convergence 2022
The Longitudinal Measurement Properties and Clinical Application of the PROMIS Fatigue 13a and 10a in Lupus
Background/Purpose: Fatigue is among the most prevalent symptoms of systemic lupus erythematosus (SLE) and is associated with patient distress, work dysfunction, and worse overall health…Abstract Number: 0634 • ACR Convergence 2022
Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis
Background/Purpose: Kidney biopsy is a gold standard for diagnosis and prognostication of lupus nephritis (LN). While interstitial fibrosis and tubular atrophy (IFTA) predict progression to…Abstract Number: 0654 • ACR Convergence 2022
Lymphatic Dysfunction and Immune Activation in Lupus
Background/Purpose: Systemic lupus erythematosus is a prototypic autoimmune disease in which patients frequently have photosensitivity. Exposure to ultraviolet radiation (UVR) causes the eruption of cutaneous…
- « Previous Page
- 1
- …
- 78
- 79
- 80
- 81
- 82
- …
- 150
- Next Page »